PhaseBio Pharmaceuticals – $46 Million IPO

Cooley advised PhaseBio Pharmaceuticals, Inc. on its $46 million initial public offering of 9,200,000 shares of common stock. The underwriters have a 30-day option to purchase an additional 1,380,000 shares. Partners Darren DeStefano and Christian Plaza led the Cooley team advising PhaseBio Pharmaceuticals.

Citigroup, Cowen and Stifel acted as the joint-book-running managers for the offering. Needham & Company acted as co-manager for the offering.

PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious orphan diseases, with an initial focus on cardiopulmonary disorders. The company’s shares now trade on the Nasdaq Global Market under the symbol “PHAS.”

Related Contacts
Darren DeStefano Partner, Reston
Christian Plaza Partner, Reston
Madison Jones Associate, Washington, DC
Jason Drory Associate, Washington, DC
Related Practices & Industries

Capital Markets Public Companies Life Sciences